Why the study?
What is the clinical and experimental evidence regarding vascular toxicity of different groups of chemotherapeutic agents?
What is the clinical and experimental evidence regarding vascular toxicity of different groups of chemotherapeutic agents?
This review highlights the growing recognition of vascular toxicity and increased cardiovascular risk associated with both anthracycline and non-anthracycline chemotherapeutic agents.
Vascular toxicity warrants clinical vigilance during chemotherapy; leaves open the need for prospective trials on mechanisms and prevention.
Cancer chemotherapy is not free of undesirable side effects. With respect to the cardiovascular system, cardiotoxicity is a well-described and potentially lethal side effect of certain chemotherapeutic agents, such as anthracyclines. However, in the last few years, several clinical studies have taken into account the fact that some non-anthracycline chemotherapy treated-patients also have a significantly increased risk of cardiovascular events. The exact mechanism of this toxicity is not known, and several possibilities, including vascular autonomic neuropathy and vascular damage, have been proposed. The aim of the present review was to collate information on the clinical and experimental evidence regarding vascular toxicity for each of the different groups of chemotherapeutic agents. The mechanisms proposed to underlie this toxicity are also discussed.
No takes yet. Share an insight, caveat, or question.
López‐Miranda et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: